MA51626A - Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce - Google Patents

Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce

Info

Publication number
MA51626A
MA51626A MA051626A MA51626A MA51626A MA 51626 A MA51626 A MA 51626A MA 051626 A MA051626 A MA 051626A MA 51626 A MA51626 A MA 51626A MA 51626 A MA51626 A MA 51626A
Authority
MA
Morocco
Prior art keywords
dna vectors
closed end
obtaining
available
acellular synthesis
Prior art date
Application number
MA051626A
Other languages
English (en)
Inventor
Ozan Alkan
Douglas Anthony Kerr
Robert Michael Kotin
Carolyn Pelletier
Matthew Stanton
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA51626A publication Critical patent/MA51626A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051626A 2018-01-19 2019-01-18 Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce MA51626A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862619392P 2018-01-19 2018-01-19

Publications (1)

Publication Number Publication Date
MA51626A true MA51626A (fr) 2020-11-25

Family

ID=67301565

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051626A MA51626A (fr) 2018-01-19 2019-01-18 Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce

Country Status (16)

Country Link
US (1) US12442015B2 (fr)
EP (1) EP3740571A4 (fr)
JP (3) JP2021511047A (fr)
KR (2) KR20250159738A (fr)
CN (1) CN111868242A (fr)
AU (1) AU2019210034B2 (fr)
BR (1) BR112020013319A2 (fr)
CA (1) CA3088984A1 (fr)
IL (1) IL275878B2 (fr)
MA (1) MA51626A (fr)
MX (1) MX2020005790A (fr)
MY (1) MY208589A (fr)
PH (1) PH12020550878A1 (fr)
SG (1) SG11202005271TA (fr)
UA (1) UA130154C2 (fr)
WO (1) WO2019143885A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
EP3833766A1 (fr) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale
KR20210090619A (ko) * 2018-11-09 2021-07-20 제너레이션 바이오 컴퍼니 대칭인 변형된 역말단반복을 포함하는 변형된 폐쇄형 DNA(ceDNA)
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
CA3147414A1 (fr) 2019-07-17 2021-01-21 Generation Bio Co. Production synthetique de vecteurs de type adn viraux adeno-associes simple brin
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230138409A1 (en) * 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
US20220243201A1 (en) * 2020-08-23 2022-08-04 Bioverativ Therapeutics Inc. Engineered itr sequences and methods of use
EP4214309A4 (fr) * 2020-09-16 2025-07-16 Generation Bio Co Vecteurs d'adn à extrémité fermée et utilisations associées pour exprimer de la phénylalanine hydroxylase (pah)
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
US20240100132A1 (en) * 2021-01-25 2024-03-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
CN112980862A (zh) * 2021-02-25 2021-06-18 通用生物系统（安徽）有限公司 一种高纯度微环dna的制备方法
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) * 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
AU2022264509A1 (en) * 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
KR20240005903A (ko) * 2021-05-07 2024-01-12 제너레이션 바이오 컴퍼니 백신 전달을 위한 비바이러스성 dna 벡터
CA3218126A1 (fr) * 2021-05-07 2022-11-10 Matthew MANGANIELLO Compositions de vecteurs d'adn non viraux lyophilisees et leurs utilisations
AU2022422134A1 (en) * 2021-12-23 2024-07-04 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct
EP4293101A1 (fr) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Réacteur à température controlée et son procédé de fabrication
CA3262218A1 (fr) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. Vecteurs d'adn non immunogènes circulaires non viraux
US20260055426A1 (en) 2022-08-19 2026-02-26 Generation Bio Co. CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
KR20250129818A (ko) * 2022-12-01 2025-08-29 제너레이션 바이오 컴퍼니 합성 단일-가닥 dna 분자 및 이를 생산하고 사용하는 방법
EP4665865A1 (fr) 2023-02-17 2025-12-24 Anjarium Biosciences AG Procédés de fabrication de molécules d'adn et compositions et utilisations associées
US11993783B1 (en) * 2023-03-27 2024-05-28 Genecraft Inc. Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
WO2026085495A1 (fr) 2024-10-18 2026-04-23 Generation Bio Co. Compositions d'acides nucléiques synthétiques partiellement simples brin, utilisations et procédés associés

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
CA2467647A1 (fr) 2001-11-30 2003-06-05 Innogenetics N.V. Utilisation therapeutique d'anticorps et de fragments associes se liant a l'interferon gamma chez des primates.
US8071332B2 (en) 2007-08-10 2011-12-06 Toto Ltd. Recombinant mammal cells, method of producing thereof, and method of producing proteins of interest
US8709778B2 (en) * 2008-10-28 2014-04-29 Xavier Danthinne Method of adenoviral vector synthesis
EP2500434A1 (fr) 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
WO2014143932A1 (fr) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
MX2018010633A (es) * 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
JP7026248B2 (ja) 2017-11-21 2022-02-25 ４ベースバイオ ソシエダー リミターダ 二本鎖ｄｎａを増幅するための方法およびキット
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
JP2022518504A (ja) * 2019-01-24 2022-03-15 ジェネレーション バイオ カンパニー 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用
CA3147414A1 (fr) * 2019-07-17 2021-01-21 Generation Bio Co. Production synthetique de vecteurs de type adn viraux adeno-associes simple brin
CA3146966A1 (fr) * 2019-07-17 2021-01-21 Generation Bio Co. Compositions et production de vecteurs d'adn a extremites fermees nickeles

Also Published As

Publication number Publication date
UA130154C2 (uk) 2025-12-03
MY208589A (en) 2025-05-19
EP3740571A4 (fr) 2021-12-08
PH12020550878A1 (en) 2021-04-05
KR102879598B1 (ko) 2025-11-03
RU2020127017A (ru) 2022-02-21
JP2025113389A (ja) 2025-08-01
BR112020013319A2 (pt) 2020-12-01
US20210071197A1 (en) 2021-03-11
IL275878B2 (en) 2026-03-01
IL275878B1 (en) 2025-11-01
WO2019143885A1 (fr) 2019-07-25
KR20200111726A (ko) 2020-09-29
MX2020005790A (es) 2020-10-28
EP3740571A1 (fr) 2020-11-25
JP2023126487A (ja) 2023-09-07
CN111868242A (zh) 2020-10-30
JP2021511047A (ja) 2021-05-06
IL275878A (en) 2020-08-31
KR20250159738A (ko) 2025-11-11
AU2019210034A1 (en) 2020-07-09
US12442015B2 (en) 2025-10-14
AU2019210034B2 (en) 2025-03-27
SG11202005271TA (en) 2020-07-29
CA3088984A1 (fr) 2019-07-25

Similar Documents

Publication Publication Date Title
MA51626A (fr) Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce
EP4229210A4 (fr) Procédés de synthèse d'oligonucléotides à l'aide de nucléotides attachés
EP3732617A4 (fr) Procédé de reconnaissance d'activité à l'aide de tubes vidéo
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
EP3675998A4 (fr) Procédé de génération d'émulsions monodispersées
EP3801544A4 (fr) Conjugués oligomères à saut d'exon pour dystrophie musculaire
EP3487290A4 (fr) Appareil de lavage d'animaux pouvant être attaché à la main
EP3775928A4 (fr) Procédé d'analyse pour glycoprotéines
EP3801775A4 (fr) Composition acrylique d'auto-durcissement pour le coiffage des cheveux
EP3833184A4 (fr) Procédé de génération d'une descendance stérile et monosexe
EP3589276A4 (fr) Produit à mâcher mou exempt d'amidon pour applications vétérinaires
EP3866692A4 (fr) Radioligands pour l'imagerie du récepteur lpa1
EP3432892A4 (fr) Antagonistes dérivés du mannose de fimh utiles pour le traitement d'une maladie
EP3839070A4 (fr) Marqueur lié à la méthylation de l'adn pour diagnostiquer une tumeur, et son application
EP4063836A4 (fr) Procédé d'analyse d'algues
EP3451153A4 (fr) Appareil et procédé d'exécution d'une opération de fonction transcendante de vecteurs
EP3644055A4 (fr) Procédé de séparation/analyse pour un mélange d'oligonucléotides
EP3834809A4 (fr) Produit cosmétique à base d'huile
EP3695377A4 (fr) Procédé d'imagerie volumétrique d'échantillon
EP4129285C0 (fr) Composés destinés à être utilisés dans la régulation de la maturation folliculaire
EP4036131A4 (fr) Procédé d'enregistrement d'image
EP3927685A4 (fr) Procédé de synthèse de composés diamide anthranilique et intermédiaires associés
EP3835427A4 (fr) Procédé de génération d'alcool 3,5-dihydroxy-4-méthoxybenzylique à partir de plancton
EP3766867A4 (fr) Procédé et appareil de récupération d'un composé à base d'amide
EP3833748A4 (fr) Compositions et procédés pour la synthèse ordonnée et continue d'adn complémentaire (adnc) à travers des modèles non continus